10-QPeriod: Q1 FY2020

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2020

Filed May 6, 2020For Securities:MRK

Summary

Merck & Co., Inc. reported a strong first quarter for 2020, with total sales reaching $12.1 billion, an increase of 11% year-over-year. This growth was primarily driven by significant increases in the oncology franchise, particularly from Keytruda, as well as contributions from alliance revenues for Lynparza and Lenvima. Vaccine sales, including Gardasil/Gardasil 9 and Pneumovax 23, also saw robust growth. The company's pharmaceutical segment profit increased by 14%, reflecting higher sales and improved cost management, partly aided by early impacts of the COVID-19 pandemic on operating expenses. Despite the overall positive performance, Merck anticipates challenges due to the COVID-19 pandemic, forecasting an unfavorable revenue impact of approximately $2.1 billion for the full year 2020. Physician-administered products, vaccines, and Keytruda are expected to be particularly affected by reduced healthcare access. In response to the uncertain environment, Merck has temporarily suspended its share repurchase program while maintaining its commitment to R&D investment and dividends. The acquisition of ArQule, Inc. for $2.7 billion in January 2020 strengthens the oncology pipeline, adding the BTK inhibitor MK-1026.

Financial Highlights

52 data points
Beta

Revenue

$12.06B

72.5% Gross Margin

Net Income

$3.22B

26.7% Net Margin

EPS (Diluted)

$1.26

Total Assets

$84.91B

Cash & Equivalents

$7.46B

Free Cash Flow

$707.00M

Financial Statements
Beta
Revenue$12.06B
Cost of Revenue$3.31B
Gross Profit$8.74B
R&D Expenses$2.21B
SG&A Expenses$2.56B
Interest Expense$212.00M
Net Income$3.22B
EPS (Basic)$1.27
EPS (Diluted)$1.26
Shares Outstanding (Basic)2.53B
Shares Outstanding (Diluted)2.55B

Key Highlights

  • 1Total sales grew 11% to $12.1 billion in Q1 2020, driven by strong performance in oncology and vaccines.
  • 2Keytruda sales surged 45% to $3.3 billion, highlighting its continued market leadership.
  • 3Alliance revenue from Lynparza and Lenvima saw substantial increases of 84% and 72%, respectively.
  • 4The company acquired ArQule, Inc. for $2.7 billion to enhance its oncology pipeline with the BTK inhibitor MK-1026.
  • 5Merck anticipates a full-year revenue impact of approximately $2.1 billion due to the COVID-19 pandemic, with a focus on managing supply chains and R&D.
  • 6Research and Development expenses increased by 14% to $2.2 billion, reflecting continued investment in clinical development and early-stage research.
  • 7The company temporarily suspended its share repurchase program due to the COVID-19 pandemic and the current operating environment.

Frequently Asked Questions

Merck's sales growth in Q1 2020 was primarily driven by strong performance in its oncology franchise, particularly Keytruda, along with increased alliance revenues from Lynparza and Lenvima. Vaccine sales, notably Gardasil/Gardasil 9 and Pneumovax 23, also contributed significantly to the overall revenue increase.

Merck anticipates a significant impact from the COVID-19 pandemic, estimating an unfavorable revenue impact of approximately $2.1 billion for the full year 2020. Physician-administered products, vaccines, and Keytruda are expected to be affected by reduced healthcare access. The company has temporarily suspended its share repurchase program but continues to prioritize R&D and dividends.

Merck acquired ArQule, Inc. for $2.7 billion in January 2020 to strengthen its oncology pipeline. The acquisition brought in ArQule's lead investigational candidate, MK-1026 (formerly ARQ 531), a novel oral Bruton's tyrosine kinase (BTK) inhibitor being evaluated for B-cell malignancies.

Research and development expenses increased by 14% to $2.2 billion in the first quarter of 2020. This increase was driven by higher expenses related to clinical development and increased investment in discovery research and early drug development, as well as higher licensing costs. Despite some delays due to COVID-19, the company continues to invest significantly in its pipeline, particularly in oncology and vaccine research.